SGLT-2 inhibitors and glucagon-like peptide-1 receptor (GLP-1R) activators are hypoglycemic drugs with demonstrated renoprotective activity [6], and SGLT-2 inhibitors can also significantly reduce urinary protein levels in the context of DN. Here, GLP1R is linked to liver dysplastic nodule.